Edmund Chiong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4904988/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Molecular Profiling Reveals a Tumor-Promoting Phenotype of Monocytes and Macrophages in Human Cancer Progression. Immunity, 2014, 41, 815-829.	6.6	240
2	Prostate cancer. Lancet, The, 2021, 398, 1075-1090.	6.3	240
3	Noninvasive Urinary Metabonomic Diagnosis of Human Bladder Cancer. Journal of Proteome Research, 2010, 9, 2988-2995.	1.8	172
4	Surface Modification of Silicone for Biomedical Applications Requiring Long-Term Antibacterial, Antifouling, and Hemocompatible Properties. Langmuir, 2012, 28, 16408-16422.	1.6	139
5	Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 1389-1395.	0.8	137
6	Inhibition of escherichia coli and proteus mirabilis adhesion and biofilm formation on medical grade silicone surface. Biotechnology and Bioengineering, 2012, 109, 336-345.	1.7	131
7	Surface modification strategies for combating catheter-related complications: recent advances and challenges. Journal of Materials Chemistry B, 2017, 5, 2045-2067.	2.9	108
8	Functionalized Mesoporous Silica Nanoparticles with Mucoadhesive and Sustained Drug Release Properties for Potential Bladder Cancer Therapy. Langmuir, 2014, 30, 6151-6161.	1.6	101
9	Randomized controlled study of mechanical percussion, diuresis, and inversion therapy to assist passage of lower pole renal calculi after shock wave lithotripsy. Urology, 2005, 65, 1070-1074.	0.5	95
10	Antifouling coating with controllable and sustained silver release for longâ€ŧerm inhibition of infection and encrustation in urinary catheters. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2015, 103, 519-528.	1.6	90
11	Urinary Metabotyping of Bladder Cancer Using Two-Dimensional Gas Chromatography Time-of-Flight Mass Spectrometry. Journal of Proteome Research, 2013, 12, 3865-3873.	1.8	88
12	The incidence, mortality, and risk factors of prostate cancer in Asian men. Prostate International, 2019, 7, 1-8.	1.2	86
13	Polymeric Nanoparticles with Encapsulated Superparamagnetic Iron Oxide and Conjugated Cisplatin for Potential Bladder Cancer Therapy. Biomacromolecules, 2012, 13, 2513-2520.	2.6	79
14	An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting. European Urology, 2020, 78, 546-569.	0.9	77
15	Extraction and quantification of biofilm bacteria: Method optimized for urinary catheters. Scientific Reports, 2018, 8, 8069.	1.6	71
16	Surface Modification of Silicone with Covalently Immobilized and Crosslinked Agarose for Potential Application in the Inhibition of Infection and Omental Wrapping. Advanced Functional Materials, 2014, 24, 1631-1643.	7.8	65
17	Port-site Hernias Occurring After the Use of Bladeless Radially Expanding Trocars. Urology, 2010, 75, 574-580.	0.5	64
18	Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma. Oncotarget, 2015, 6, 13539-13549.	0.8	64

EDMUND CHIONG

#	Article	IF	CITATIONS
19	A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings. European Urology, 2019, 75, 558-561.	0.9	64
20	Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells. Clinical Cancer Research, 2011, 17, 2863-2873.	3.2	57
21	Mach–Zehnder interferometer (MZI) point-of-care system for rapid multiplexed detection of microRNAs in human urine specimens. Biosensors and Bioelectronics, 2015, 71, 365-372.	5.3	55
22	Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer, 2007, 109, 1097-1105.	2.0	53
23	Mucoadhesive polyacrylamide nanogel as a potential hydrophobic drug carrier for intravesical bladder cancer therapy. European Journal of Pharmaceutical Sciences, 2015, 72, 57-68.	1.9	49
24	Thiol-ol Chemistry for Grafting of Natural Polymers to Form Highly Stable and Efficacious Antibacterial Coatings. ACS Applied Materials & Interfaces, 2017, 9, 1847-1857.	4.0	44
25	Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. Lancet Oncology, The, 2013, 14, e524-e534.	5.1	42
26	Metabonomic Profiling of Bladder Cancer. Journal of Proteome Research, 2015, 14, 587-602.	1.8	40
27	Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU International, 2017, 119, 684-691.	1.3	36
28	Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4-10 ng ml ⁻¹ . Asian Journal of Andrology, 2017, 19, 286.	0.8	36
29	Management of patients with advanced prostate cancer in the Asia Pacific region: â€~realâ€world' consideration of results from the Advanced Prostate Cancer Consensus Conference <scp>(APCCC)</scp> 2017. BJU International, 2019, 123, 22-34.	1.3	32
30	Management of kidney cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncology, The, 2012, 13, e482-e491.	5.1	30
31	PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein. Nature Communications, 2019, 10, 2484.	5.8	30
32	NRAMP1 and hGPX1 Gene Polymorphism and Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer. European Urology, 2011, 59, 430-437.	0.9	29
33	Co-delivery of peptide-modified cisplatin and doxorubicin via mucoadhesive nanocapsules for potential synergistic intravesical chemotherapy of non-muscle-invasive bladder cancer. European Journal of Pharmaceutical Sciences, 2016, 84, 103-115.	1.9	29
34	Aspects of urinary tract infections and antimicrobial resistance in hospitalized urology patients in Asia: 10-Year results of the Global Prevalence Study of Infections in Urology (GPIU). Journal of Infection and Chemotherapy, 2018, 24, 278-283.	0.8	29
35	Comparison of metrics for the evaluation of medical segmentations using prostate MRI dataset. Computers in Biology and Medicine, 2021, 134, 104497.	3.9	29
36	Restriction of in vivo infection by antifouling coating on urinary catheter with controllable and sustained silver release: a proof of concept study. BMC Infectious Diseases, 2018, 18, 370.	1.3	28

EDMUND CHIONG

#	Article	IF	CITATIONS
37	Tryptophan–kynurenine ratio as a biomarker of bladder cancer. BJU International, 2021, 127, 445-453.	1.3	19
38	Quantitative 18F-fluorocholine positron emission tomography for prostate cancer: correlation between kinetic parameters and Gleason scoring. EJNMMI Research, 2017, 7, 25.	1.1	17
39	Urinary markers in screening patients with hematuria. World Journal of Urology, 2008, 26, 25-30.	1.2	16
40	Metabolic signatures of renal cell carcinoma. Biochemical and Biophysical Research Communications, 2015, 460, 938-943.	1.0	16
41	Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 438-451.	1.3	16
42	The Use of Short Tandem Repeat Profiling to Characterize Human Bladder Cancer Cell Lines. Journal of Urology, 2009, 181, 2737-2748.	0.2	14
43	Detection of Clinical Mesenchymal Cancer Cells from Bladder Wash Urine for Real-Time Detection and Prognosis. Cancers, 2019, 11, 1274.	1.7	14
44	Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naÃīve, metastatic castration-resistant prostate cancer. Medicine (United States), 2017, 96, e7223.	0.4	13
45	Robotic kidney autotransplantation in a porcine model: a procedure-specific training platform for the simulation of robotic intracorporeal vascular anastomosis. Journal of Robotic Surgery, 2018, 12, 693-698.	1.0	13
46	United in Fight against prOstate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia. BJU International, 2020, 125, 541-552.	1.3	12
47	Potentiating anti-cancer chemotherapeutics and antimicrobials <i>via</i> sugar-mediated strategies. Molecular Systems Design and Engineering, 2020, 5, 772-791.	1.7	12
48	Wirelessly Activated Nanotherapeutics for In Vivo Programmable Photodynamic hemotherapy of Orthotopic Bladder Cancer. Advanced Science, 2022, 9, e2200731.	5.6	12
49	Role of cytoreductive nephrectomy in renal cell carcinoma. Future Oncology, 2009, 5, 859-869.	1.1	11
50	New therapies for non-muscle-invasive bladder cancer. World Journal of Urology, 2010, 28, 71-78.	1.2	11
51	Prostate cancer in Asia: design of a patient registry to inform real-world treatments, outcomes, and quality of life. Prostate International, 2019, 7, 108-113.	1.2	11
52	Evaluation of Multimodal Algorithms for the Segmentation of Multiparametric MRI Prostate Images. Computational and Mathematical Methods in Medicine, 2020, 2020, 1-12.	0.7	11
53	Antegrade ureteral intussusception: A rare complication of percutaneous endopyelotomy. Urology, 2004, 64, 1231.	0.5	9
54	The Good, the Bad, and the Ugly of the COVID-19 Pandemic in a Urology Residency Program in Singapore. Urology, 2020, 142, 244-245.	0.5	9

Edmund Chiong

#	Article	IF	CITATIONS
55	Preserving Operational Capability While Building Capacity During the COVID-19 Pandemic: A Tertiary Urology Centre's Experience. Urology, 2020, 142, 36-37.	0.5	8
56	Asia prostate cancer study (A-CaP Study) launch symposium. Prostate International, 2016, 4, 88-96.	1.2	7
57	Report of the Second Asian Prostate Cancer (A-CaP) Study Meeting. Prostate International, 2017, 5, 95-103.	1.2	7
58	A prospective international randomized phase II study evaluating the food effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC) Journal of Clinical Oncology, 2017, 35, 176-176.	0.8	7
59	Clinical studies investigating the use of leuprorelin for prostate cancer in Asia. Prostate International, 2020, 8, 1-9.	1.2	6
60	Psychological health among surgical providers during the COVID-19 pandemic: a call to action. British Journal of Surgery, 2020, 107, e459-e460.	0.1	6
61	A Tubular Dual-Roller Bending Mechanism Toward Robotic Transurethral Prostate Biopsy. IEEE/ASME Transactions on Mechatronics, 2021, 26, 2483-2494.	3.7	6
62	Beyond diabetes mellitus: role of metformin in non-muscle-invasive bladder cancer. Singapore Medical Journal, 2022, 63, 209-213.	0.3	6
63	Review of Clinical Manifestations of Biochemically-advanced Prostate Cancer Cases. Asian Journal of Surgery, 2005, 28, 202-206.	0.2	5
64	Managing advanced prostate cancer in the Asia Pacific region: "Realâ€world―application of Advanced Prostate Cancer Consensus Conference 2019 statements. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 686-695.	0.7	5
65	Report of the third Asian Prostate CancerÂstudy meeting. Prostate International, 2019, 7, 60-67.	1.2	4
66	Impact of the COVID-19 Pandemic on the Urology Residency Match in Singapore. Urology, 2020, 143, 272-273.	0.5	4
67	The START (Surgical Triage And Resource Allocation Tool) of Surgical Prioritization During the COVID-19 Pandemic. Urology, 2020, 142, 32-35.	0.5	4
68	Comparing outcomes of transperineal to transrectal prostate biopsies performed under local anaesthesia. BJUI Compass, 2022, 3, 197-204.	0.7	3
69	Angiosarcoma of graft nephrectomy site: genetic profiling reveals recipient origin. Histopathology, 2012, 60, 1158-1160.	1.6	2
70	The Role of Vitamin D Receptor Polymorphisms in Predicting the Response to Therapy for Nonmuscle Invasive Bladder Carcinoma. Journal of Urology, 2018, 200, 737-742.	0.2	2
71	Receptor-Targeting Drug and Drug Carrier for Enhanced Killing Efficacy against Non-Muscle-Invasive Bladder Cancer. ACS Applied Bio Materials, 2019, 2, 3763-3773.	2.3	2
72	Pre-Clinical Proof-of-Concept Study of a Bladder Irrigation Feedback System for Gross Haematuria in a Lab Setup. Multimodal Technologies and Interaction, 2020, 4, 59.	1.7	2

EDMUND CHIONG

#	Article	IF	CITATIONS
73	Gmcsf and Ifnα gene therapy improves the response to BCG immunotherapy in a murine model of bladder cancer. Future Oncology, 2020, 16, 1179-1188.	1.1	2
74	Right Place, Right Time: Serendipitous Opportunities in a Urology Fellowship Disrupted by the COVID-19 Pandemic. Urology, 2020, 143, 269.	0.5	2
75	Intravesical High Dose BCG Tokyo and Low Dose BCG Tokyo with GMCSF+IFN α Induce Systemic Immunity in a Murine Orthotopic Bladder Cancer Model. Biomedicines, 2021, 9, 1766.	1.4	2
76	Predictive biomarkers of response to bacillus Calmetteâ€Guérin immunotherapy and bacillus Calmetteâ€Guérin failure for nonâ€muscle invasive bladder cancer. International Journal of Urology, 2022, 29, 807-815.	0.5	2
77	A model of optimising the needle insertion through deflection studies. International Journal of Biomedical Engineering and Technology, 2014, 16, 97.	0.2	1
78	Tailoring Soft Nanoparticles for Potential Application as Drug Carriers in Bladder Cancer Chemotherapy. ACS Symposium Series, 2016, , 167-195.	0.5	1
79	Patent processus vaginalis as a conduit for tumoral seeding: a rare presentation of port site metastasis. ANZ Journal of Surgery, 2019, 89, E216-E217.	0.3	1
80	Combination Bacillus Calmette–Guérin and indoleamine 2,3â€dioxygenase 1 inhibitor therapy of murine orthotopic bladder cancer. BJU International, 2020, 126, 554-556.	1.3	1
81	Can artificial intelligence optimize case selection for hemiâ€gland ablation?. BJU International, 2020, 125, 333-334.	1.3	1
82	Transitioning to robotic partial nephrectomy with a team-based proctorship achieves the desired improved outcomes over open and laparoscopic partial nephrectomy. Updates in Surgery, 2021, 73, 1189-1196.	0.9	1
83	Clinical Aspects and Investigations in Genitourinary Cancer. , 2018, , 1-17.		0
84	Clinical Aspects and Investigations in Genitourinary Cancer. , 2019, , 19-36.		0
85	Editorial Comment to DDD score for renal tumor: An intuitive and comprehensive anatomical scoring system to access the outcomes of retroperitoneal laparoscopic partial nephrectomy. International Journal of Urology, 2019, 26, 456-457.	0.5	0
86	Re: Kristian D. Stensland, Todd M. Morgan, Alireza Moinzadeh, et al. Considerations in the Triage of Urologic Surgeries During the COVID-19 Pandemic. Eur Urol 2020;77:663–6. European Urology, 2020, 78, e135-e136.	0.9	0
87	Polymorphism in autophagy gene ATG2B is not associated with bladder cancer recurrence after intravesical Bacillus Calmette-Guerin (BCG) immunotherapy in Asian patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 238.e1-238.e7.	0.8	0
88	Cost-effectiveness of MRI targeted biopsy strategies for diagnosing prostate cancer in Singapore. BMC Health Services Research, 2021, 21, 909.	0.9	0
89	Renal Cancer. , 2015, , 395-403.		0
90	Tryptophan Metabolism and IDO/TDO Expression in Bladder Cancer: A Case ontrol Study in Singapore. FASEB Journal, 2018, 32, 566.13.	0.2	0

#	Article	IF	CITATIONS
91	ELIGANT: a Phase 4, interventional, safety study of leuprorelin acetate (ELIGARD®) in Asian men with prostate cancer. Translational Andrology and Urology, 2022, 11, 179-189.	0.6	0
92	Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castrationâ€sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placeboâ€controlled, phase III TITAN study. International Journal of Urology, 2022, 29, 541-541.	0.5	0
93	Utility of serum biomarkers for predicting cancer in patients with previous negative prostate biopsy. World Journal of Urology, 0, , .	1.2	О